澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

MESOBLAST LTD

2.205

+0.0150.68%

成交量：195.94万

成交额：433.87万

市值：28.45亿

市盈率：-20.83

高：2.260

开：2.220

低：2.190

收：2.190

52周最高：3.310

52周最低：1.515

股本：12.90亿

流通股本：7.86亿

量比：0.67

换手率：0.25%

股息：- -

股息率：- -

每股收益(TTM):-0.106

每股收益(LYR):-0.122

净资产收益率：-18.22%

总资产收益率：-6.16%

市净率：3.44

市盈率(LYR):-18.12

数据加载中...

总览公司新闻资讯公告

异动解读 | Mesoblast公布上半年业绩亏损4020万美元，股价盘中大跌7.23%

Mesoblast公布上半年总收入5130万美元

异动解读 | Mesoblast核心产品收入预期乐观，股价盘中大涨5.79%

Mesoblast Limited预计2026财年Ryoncil净收入将达1.1亿至1.2亿美元

FDA确认Rexlemestrocel-L在疼痛强度上展现积极效果，12个月背痛减轻数据支持产品疗效

独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib

异动解读 | Mesoblast股价盘中大涨6.72%，预计季度收入超3000万美元

Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售

Mesoblast宣布James M. O’Brien被任命为首席财务官

新闻稿：詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官

BUZZ-奥布莱恩出任美国分部财务总监，Mesoblast 的澳大利亚股票攀升

Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断

Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MSB.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.205,"timestamp":1774497143495,"preClose":2.19,"halted":0,"volume":1959357,"delay":0,"changeRate":0.0068493150684932076,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10585637425554564,"marketStatus":"交易中","change":0.015,"latestTime":"03-26 14:52:29 AEDT","open":2.22,"high":2.26,"low":2.19,"amount":4338747,"amplitude":0.031963,"askPrice":2.21,"askSize":64182,"bidPrice":2.2,"bidSize":42015,"shortable":3,"etf":0,"ttmEps":-0.10585637425554564,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774501200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.19,"openAndCloseTimeList":[[1774479600000,1774501200000]],"volumeRatio":0.674089,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.19,"auctionPrice":2.22,"auctionVolume":223939,"auctionTime":1774479546233,"referenceTime":1774431003096,"auction":1,"marketStatus":"盘前竞价","timestamp":1774479546233}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.121658,"volumeRatio":0.674089,"shares":1290302187,"dividePrice":0,"high":2.26,"amplitude":0.031963,"preClose":2.19,"low":2.19,"week52Low":1.515,"pbRate":"3.44","psRate":"30.25","week52High":3.31,"institutionHeld":0,"latestPrice":2.205,"committee":-0.208735,"eps":-0.10585637425554564,"divideRate":0,"volume":1959357,"delay":0,"ttmEps":-0.10585637425554564,"open":2.22,"prevYearClose":2.72,"prevWeekClose":2.06,"prevMonthClose":2.24,"prevQuarterClose":2.72,"fiveDayClose":2.07,"twentyDayClose":2.42,"sixtyDayClose":2.8,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1127354637","title":"异动解读 | Mesoblast公布上半年业绩亏损4020万美元，股价盘中大跌7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127354637","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127354637?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 10:22","pubTimestamp":1772158948,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中股价大跌7.23%，引起了市场的广泛关注。消息面上，公司公布了上半年的财务业绩，虽然总收入达到5130万美元，但归属于公司的亏损高达4020万美元。这一显著的亏损数据可能引发了投资者对公司盈利能力和财务状况的担忧，从而导致股价在交易时段内出现大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1171017622","title":"Mesoblast公布上半年总收入5130万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171017622","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171017622?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 10:15","pubTimestamp":1772158552,"startTime":"0","endTime":"0","summary":"2月27日（路透社）—— Mesoblast Ltd 发布中期业绩公告：*上半年总收入达5130万美元* *归属于公司亏损为4020万美元*\n更多公司相关报道可参考股票代码MSB.AX。\n（信息来源：路透社简报；发布时间：2026年2月27日02:03:10 GMT）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0},{"id":"1164807609","title":"异动解读 | Mesoblast核心产品收入预期乐观，股价盘中大涨5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164807609","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164807609?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 07:03","pubTimestamp":1772146980,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 今日盘中大涨5.79%，引起了市场的广泛关注。消息面上，Mesoblast Limited预计其核心产品Ryoncil在2026财年的全年净收入将介于1.1亿美元至1.2亿美元之间，这一积极的财务预期反映了公司对产品商业化前景的信心，可能提振了投资者情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1110626132","title":"Mesoblast Limited预计2026财年Ryoncil净收入将达1.1亿至1.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110626132","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110626132?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 05:53","pubTimestamp":1772142784,"startTime":"0","endTime":"0","summary":"生物技术企业Mesoblast Limited最新预测显示，其核心产品Ryoncil在2026财年的全年净收入预计将介于1.1亿美元至1.2亿美元之间。这一预期反映了公司对产品商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MESO","BK4139","MSB.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"1118834527","title":"FDA确认Rexlemestrocel-L在疼痛强度上展现积极效果，12个月背痛减轻数据支持产品疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118834527","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118834527?lang=zh_cn&edition=fundamental","pubTime":"2026-01-19 08:02","pubTimestamp":1768780936,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1100916668","title":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"gpt_icon":0},{"id":"1115028816","title":"异动解读 | Mesoblast股价盘中大涨6.72%，预计季度收入超3000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115028816?lang=zh_cn&edition=fundamental","pubTime":"2025-11-26 07:03","pubTimestamp":1764111792,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Mesoblast Limited今日盘中股价大涨6.72%，引起投资者广泛关注。此轮涨势主要源于公司发布的积极财务预期。Mesoblast预计截至2025年12月31日的季度毛收入将超过3000万美元，这一收入主要来自其重磅产品Ryoncil的销售。Ryoncil是Mesoblast的主打产品，用于治疗急性移植物抗宿主病。该产品的强劲销售表现不仅直接提升了公司的财务状况，也增强了投资者对Mesoblast长期发展前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1109683405","title":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","url":"https://stock-news.laohu8.com/highlight/detail?id=1109683405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109683405?lang=zh_cn&edition=fundamental","pubTime":"2025-11-25 22:45","pubTimestamp":1764081909,"startTime":"0","endTime":"0","summary":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MESO","MSB.AU","BK7067","BK4139","BK7501"],"gpt_icon":0},{"id":"1182398223","title":"Mesoblast宣布James M. O’Brien被任命为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1182398223","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182398223?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:14","pubTimestamp":1763367269,"startTime":"0","endTime":"0","summary":"11月17日 - Mesoblast Ltd：James M. O’Brien被任命为Mesoblast的首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0},{"id":"1195991725","title":"新闻稿：詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1195991725","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195991725?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 14:56","pubTimestamp":1763362561,"startTime":"0","endTime":"0","summary":"纽约，2025年11月17日-- 美莎比信托，全球领先的用于治疗炎症性疾病的同种异体细胞药物公司，今天宣布，在公司向一个完全整合的商业组织转型之际，任命詹姆斯·M·奥布莱恩为其美国首席财务官。詹姆斯在财务管理和规划的各个方面拥有丰富经验，职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公私公司中度过。本发布已获首席执行官授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK7501","BK4139","BK4022","R","MESO","CFO","MSC","BK4006","BK4150","BK7508","BK4575","BK7067","BMS","MSB.AU","MSB"],"gpt_icon":0},{"id":"2584924916","title":"BUZZ-奥布莱恩出任美国分部财务总监，Mesoblast 的澳大利亚股票攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924916","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924916?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 09:11","pubTimestamp":1763341883,"startTime":"0","endTime":"0","summary":"11月17日 - ** 在澳大利亚证券交易所上市的炎症性疾病药物生产商Mesoblast MSB.AX的股价上涨3.6%，达到2.3澳元，结束了连续两个交易日的下跌。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL4T3WT01H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","CGTX","BK7508","BK4007","BK7501"],"gpt_icon":0},{"id":"1116191251","title":"Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1116191251","media":"投资观察","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116191251?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 09:45","pubTimestamp":1762307124,"startTime":"0","endTime":"0","summary":"11月5日（路透社） - Mesoblast Ltd：*MESOBLAST将于下月与FDA会面，讨论Rexlemestrocel-L和阿片类药物戒断* 进一步公司报道：MSB.AX","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1199521939","title":"Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1199521939","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199521939?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 06:59","pubTimestamp":1762297168,"startTime":"0","endTime":"0","summary":"Mesoblast将于下月与FDA会面，讨论Rexlemestrocel-L和药物戒断的相关事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7508","BK7501","BK7067","MSB.AU","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}